Treatment of Topical Ketorolac Gel in Acute Gouty Flare
Status:
NOT_YET_RECRUITING
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This study will be a phase 1, open-label, bioavailability, safety and PK study of topically applied transcutaneous ketorolac tromethamine gel 12.5% (/w) (NOV-1776) versus intravenous administration of approved ketorolac tromethamine injection, USP (15mg/mL) comparator in healthy volunteers, including an evaluation of safety, tolerability, and efficacy in gout participants with flare-up.